Secukinumab has received FDA approval as a new treatment option in psoriasis. A panel of experts tackles this drug’s uses, benefits, and drawbacks.
Treatments for Plaque Psoriasis
Researchers analyzed emerging oral drugs for psoriasis and concluded “… the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biologic therapies.
New Study suggests dermatologists completing a PI CME on psoriasis significantly improved in important patient care aspects. Learn more.
Can targeting differentially regulated proteins reverse or prevent disease?
A phase 3 clinical program is under way to further evaluate the efficacy and safety of Cimzia (certolizumab pegol, UCB) in adult patients with moderate to severe chronic plaque psoriasis.
The FDA announced Wednesday, January 21, that it approved secukinumab (Cosentyx, Novartis Pharmaceuticals Corporation) as a treatment for adults with moderate-to-severe plaque psoriasis.
Kevin D. Cooper, M.D., professor and chair of dermatology at Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, and Steven R. Feldman, M.D., Ph.D., professor of dermatology, Wake Forest University School of Medicine, Winston-Salem, N.C., weigh in on important gaps in dermatology research today.
A report published in January 2014 identified several gaps in psoriasis research and recommended research targets to address these gaps.
Getting patients to use their prescriptions is another story-one that's shockingly understudied in dermatology. Just what works to improve medication adherence has stumped researchers outside dermatology. Several studies are cited.
Data from a recently published study reveal systemic steroids are often the choice of therapy for clinicians based in the US who treat psoriasis, yet this practice is not endorsed in clinical practice guidelines.